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DNA methylation differences in monozygotic twin
pairs discordant for schizophrenia identifies
psychosis related genes and networks
Christina A Castellani1, Benjamin I Laufer1, Melkaye G Melka1, Eric J Diehl1, Richard L O’Reilly2 and Shiva M Singh1,2*

Abstract
Background: Despite their singular origin, monozygotic twin pairs often display discordance for complex disorders
including schizophrenia. It is a common (1%) and often familial disease with a discordance rate of ~50% in
monozygotic twins. This high discordance is often explained by the role of yet unknown environmental, random,
and epigenetic factors. The involvement of DNA methylation in this disease appears logical, but remains to be
established.
Methods: We have used blood DNA from two pairs of monozygotic twins discordant for schizophrenia and their
parents in order to assess genome-wide methylation using a NimbleGen Methylation Promoter Microarray.
Results: The genome-wide results show that differentially methylated regions (DMRs) exist between members
representing discordant monozygotic twins. Some DMRs are shared with parent(s) and others appear to be de
novo. We found twenty-seven genes affected by DMR changes that were shared in the affected member of two
discordant monozygotic pairs from unrelated families. Interestingly, the genes affected by pair specific DMRs
share specific networks. Specifically, this study has identified two networks; “cell death and survival” and a “cellular
movement and immune cell trafficking”. These two networks and the genes affected have been previously implicated
in the aetiology of schizophrenia.
Conclusions: The results are compatible with the suggestion that DNA methylation may contribute to the discordance
of monozygotic twins for schizophrenia. Also, this may be accomplished by the direct effect of gene specific
methylation changes on specific biological networks rather than individual genes. It supports the extensive genetic,
epigenetic and phenotypic heterogeneity implicated in schizophrenia.
Keywords: Monozygotic Twins, Schizophrenia, DNA Methylation, MeDIP, Methylation Array, Differentially Methylated
Regions (DMRs), snoRNA, Histone Clusters

Background
Monozygotic twins (MZ) have long been used to ascertain
the genetic and environmental contributions to complex
diseases, including schizophrenia [1]. Their unique aptness
lies in originating from the genetic content of a single zygote and sharing most in utero and postnatal environments.
Historically, the concordance and discordance for a disease between MZ twins has been attributed to unspecified
genetic and environmental factors, respectively [2]. The
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recent advent of comprehensive genetic and epigenetic
technologies has added a new supremacy to such studies.
Studies of this kind hold the potential to identify specific
mechanisms that contribute to the causation of disease
[3,4]. The first stage in these studies is to identify differences between monozygotic discordant (MZD) twins that
are expected to be genetically identical. The results during
the last few years have established that differences do exist
at the genetic [5,6] as well as epigenetic [7-9] levels. The
results argue that MZ twins are similar, but not identical
[6]. Also, the rare de novo mutations may take place during developmental mitosis during ontogeny [6].
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Interestingly, methylation differences between identical
twins have been reported as early as in newborns [10].
DNA methylation is reported to increase with age [11] and
accordingly, the methylation differences between monozygotic twins increases with age [7]. Epigenetic differences
between MZ twins include features like X-inactivation,
genomic imprinting, or differential methylation of genes,
and may cause MZ twin pairs to diverge, leading to disease
discordance [3,12]. Studies of this kind have concluded that
no two individuals are alike; not even identical twins [6].
However, the genetic similarity between MZ twins is comparable to no other two individuals. In addition, identical
twins are matched for age, sex, maternal environment, and
population cohort effects - making them the best matched
control available [13]. Indeed, MZ twins provide a unique
backdrop to assess epigenetic states that are shared due to
inheritance or common environments, as well as differences that may be in response to individual specific exposures or random events [7-9,14,15]. Such changes, if
operational, may allow monozygotic twins to develop discordance for almost any trait through reprogramming of
gene expression via epigenetic mechanisms which may increase liability to disease [16]. This is particularly relevant
in neurodevelopmental disorders, especially schizophrenia,
and reports are now accumulating from twin studies to
support an epigenetic model of disease contribution. For
instance, it has been shown that the schizophrenic twin
from a pair of discordant twins is epigenetically more
similar to the affected concordant twins than to his own
unaffected co-twin at the DRD2 gene [17]. In addition,
methylation of genes in blood samples of twins discordant
for schizophrenia, including medication free patients,
shows hypermethylation and hypomethylation of several
genes [18,19].
Indeed, the molecular results accumulating on schizophrenia are encouraging and include many recent reports of associations between DNA methylation and
schizophrenia [12,20,21]. The evidence is also emerging
for lncRNAs as an important epigenetic contributor to
schizophrenia [22].
The research presented here identifies genes whose
methylation is altered in schizophrenia patients as
compared to their unaffected twin using genome-wide
assessment by Methylated DNA Immunoprecipitation
(MeDIP) on a Nimblegen Human DNA Methylation
Microarrays. It uses blood DNA from two sets of
monozygotic twin pairs discordant for schizophrenia
and their parents. The results identify DNA methylation differences between MZD twins in two families
discordant for schizophrenia. Also, the patients across
families share affected genes, and more importantly,
biological networks. The implications of the results
will require reports on an increasing number of MZD
twins but are particularly promising given that the

Page 2 of 12

genes and networks identified are similar to accumulating reports.

Methods
This study on monozygotic twins received ethics approval by the University of Western Ontario’s Committee on research involving human subjects. All subjects
provided written informed consent to participate in this
study. Further, they have agreed to the sharing of data
(genetic and clinical) in any publication. All of the patients were adults at the time of consent. Capacity for
consent was ensured using three measures 1) Schizophrenic patients gave consent only during a “normal”
phase (no psychosis present), 2) Both twins of the twin
pair were present and gave consent at the same time (the
normal twin and their affected sibling), 3) If R.O’Reilly felt
that capacity to consent was compromised, the patients
were not included in our study. They were interviewed
and clinically assessed by a single senior Psychiatrist (R.
O’Reilly) using the SCID-I and SCID-II [23,24]. Past clinical notes were available to aid in diagnosis. Both families
were comprised of identical female twins. The twins from
Family 1 (Figure 1) were Caucasian females aged 43. The
affected member of twin pair 1 was diagnosed with schizoaffective disorder at age 27. The twins were discordant
for 16 years at the time of sample collection. The twins
from Family 2 (Figure 1) were Afro-American females
aged 53. The affected member of twin pair 2 was diagnosed with schizophrenia at age 22. The twins were
discordant for 31 years at the time of sample collection.
The twins and their parents (Figure 1) included in this
study contributed whole blood samples for DNA isolation.
Both pairs of monozygotic twins were female twins. DNA
was extracted from whole blood using the 5 Prime Perfect
Pure DNA Blood Kit (Gaithersburg, MD, USA), following
the manufacturer’s protocol. It should be noted that the
Father of Twin Pair 2 was diagnosed with Chronic
Leukemia (CLL) at age 69. The affected patient from

Figure 1 Pedigrees of families included in the study. Shaded circles
represent the affected twins.

Castellani et al. BMC Medical Genomics (2015) 8:17

Family 1 was treated for schizophrenia symptoms using a
combination of the medications Seroquel, Effexor and
Topiramate. The affected patient from Family 2 was
treated for schizophrenia symptoms using a combination
of the medications Clozapine, Divalproex and Benztropine.
Zygosity was confirmed by Affymetrix 6.0 microarray and
specifically using the Affymetrix Genotyping Console 4.0
concordance feature [6].
The genomic DNA was processed at ArrayStar Inc
(Rockville, MD, USA); this included the methylated
DNA immunoprecipitation (MeDIP), sample labeling,
and hybridization to the NimbleGen Human DNA Methylation Promoter Plus CpG Island 720k Array. The NimbleGen Human DNA Methylation 3x720k CpG Island Plus
RefSeq Promoter Microarray is a multiplex slide with 3
identical arrays per slide. Each Roche Nimblegen Inc
(Madison, MI, USA) array covers 27,728 annotated CpG
islands as well as 22,532 promoters of the RefSeq genes
derived from the UCSC RefFlat files. Median-centering,
quantile normalization, and linear smoothing was performed by Bioconductor packages Ringo, limma, and
MEDME at ArrayStar. Lastly, in order to compare the two
groups’ differentially enriched regions the average of the
log2-ratio values for each group (i.e. experimental patient
[E] and healthy control [C]) was used to calculate M’ value
(defined by the following equation) for each probe.
M’ ¼ Averageðlog2 MeDIPE =InputE Þ
− Averageðlog2 MeDIPC =InputC Þ
The differential enrichment peaks were filtered according to the following criteria:
i). At least one of the two groups has a median (log2
MeDIP/Input) > =0.3 and M’> 0.
ii). At least half of probes in a peak may have coefficient
of variability (CV) < = 0.8 in both groups.
Before hybridization to the array, genomic DNA was
sonicated to random fragments in size of about 200–
1000 bp. Immunoprecipitation of methylated DNA was
performed using Biomag™ magnetic beads coupled to a
mouse monoclonal antibody against 5-methylcytidine.
The immunoprecipitated DNA was eluted and purified
by phenol chloroform extraction and ethanol precipitation. The total input and immunoprecipitated DNA were
labeled with Cy3- and Cy5-labeled random 9-mers.
Scanning was performed with the Axon GenePix 4000B
microarray scanner. Raw data was extracted as pair files
by NimbleScan software.
The pair files were analyzed with the tiling workflow in
Partek Genomics Suite® version 6.6 (St. Louis, Missouri,
USA). Nimblegen scan pair files (635 nm and 532 nm) for
each sample were annotated against hg18 and enriched
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regions were detected using a two-way ANOVA between
an affected twin and their unaffected co-twin. The
enriched regions settings were set at a minimum p-value
of 0.001 and the number of probes to call a region was set
at a minimum of 4. MAT scores were generated for each
differentially methylated region. Overlapping genes were
then identified as those RefSeq (2014-04-29 version) genes
that were either within the gene or 5000 bp upstream or
3000 downstream of the gene. Differentially methylated
regions (DMRs) in each affected twin were identified in relation to the pattern in the well twin. Also, the presence or
absence of each DMR was assessed as familial or de novo
based on their presence or absence in Mom and/or Dad.
The identified genes with significant changes in DNA
methylation between twins discordant for schizophrenia
(DMRs) were then analyzed using Ingenuity Pathway
Analysis (Ingenuity Systems Inc, CA, USA) towards
identification of networks and canonical pathways overrepresented in the enriched genes. Also, pathway analysis and gene ontology analysis were conducted using
Partek Pathways (Fishers Exact Test) and Enrichr [25].
Shared genes were annotated with imprinting data from
GeneImprint (http://www.geneimprint.com) and The
Catalogue of Parent of Origin Effects (http://igc.otago.ac.
nz/home.html).

Results
We report the genome-wide analysis of methylation differences in two families with monozygotic twins discordant for schizophrenia using the NimbleGen Human
DNA Methylation Promoter Plus CpG Island 720k
Array. The data was analyzed with Partek Genomics
Suite and yielded three main lines of results presented
below:
MZ twins show differences in DNA Methylation profiles

The genome-wide DNA methylation profiles have revealed differentially methylated peaks and regions
(DMRs) between the MZ twin pairs in our study (p ≤
0.001). Further, the availability of parental data has
allowed us to assess each DMR for its presence/absence
in the two parents. The results show that methylation
profiles in twins include both shared and de novo events
(arising from environmental exposures or random
events). We note that in Family 1 as well as in Family 2
(Figure 1), most of the DMRs appear de novo (are not
found in Mom or Dad) as only 25% and 13% of the DMRs,
respectively, were present in either Mom or Dad. The results have also allowed identification of specific genes that
are differentially methylated between the affected twin and
their identical unaffected twin. Specifically, we note that
138 genes are differentially methylated in the twin pair
from Family 1 (see Additional file 1) and 330 genes are differentially methylated in Family 2 (see Additional file 2). A
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visual representation of these results is given in Figure 2,
specifically the outside track of the Circos diagram represents DMRs in Family 2, the middle track represents
DMRs in Family 1 and the inside track represents 27 overlapping DMRs annotated with gene identity. An overlap
between the DMRs present in the affected member of the
two unrelated families (Figure 3) suggests that most (8092%) of the DMRs are twin pair specific. Chromosome 1
(19 and 36 DMRs respectively) and Chromosome 15 (21
and 30 DMRs respectively) show the most DMRs in Family 1 as well as in Family 2. Family 2 also has a large number of DMRs on Chromosome 19 (30 DMRs).
MZ twins discordant for schizophrenia share genomic
regions of differential methylation

Figure 3 shows 27 genes that were differentially methylated in two affected twins. Of the genes that showed
methylation differences in both sets of twins, 24 were increased in methylation status in the affected twins. The
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list of genes (Table 1) identified shared common regions
with exact DMR start/end locations in the two patients.
The exception was the PTPRN2 (Entrez Gene: 5799),
TTYH3 (Entrez Gene: 80727) and ZFP41 (Entrez Gene:
286128) regions where the DMRs were found to be
nearby (Table 1). Also, the sequences affected are specific to the promoter regions as expected.
Interestingly, a subset of common genes identified (5
genes), belong to either the HIST2H cluster on Chromosome 1 or the HIST1H region on Chromosome 6 (Table 1).
Further, 17 of the 27 genes belong to either the SNORD115
(Entrez Gene: 692218) or SNORD116 (Entrez Gene:
692236) clusters on chromosome 15. All seventeen of the
SNORD genes identified in two patients are known to be
genomically imprinted and produce ncRNA transcripts
that undergo extensive processing and form many functional classes of non-coding regulatory RNA (Table 1). This
region can be seen in detail in Figure 4 that extends from
the SNRPN gene (Entrez Gene: 6638) to the UBE3A gene

Figure 2 Differential methylation in two twin pairs in a Circos plot covering all chromosomes. Circos plot representing differentially methylated
regions in each affected twin as well as shared regions between both affected twins in our study. Red represents a decrease in methylation in
the affected twin and blue represents an increase in methylation in the affected twin. The outside track represents differentially methylated regions in
the affected member of Family 2, the middle track represents differentially methylated regions in the affected member of Family 1 and the inside track
represents the shared regions found in both unrelated affected twins. Affected genes are labeled.
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Figure 3 Overlap of differentially methylation regions. Venn diagram showing the number of genes differentially methylated in each patient (138 and
330 respectively) as well as the genes enriched in both affected twins in the study (27).

(Entrez Gene: 7337) and encompasses the SNORD115 and
SNORD116 gene families. Ingenuity Pathway Analysis
(IPA) involving the shared genes has identified Protein
Kinase A Signaling as the most enriched canonical pathway (p = 3.09E-04). In addition, Granzyme A Signaling
(p = 6.83E-03), G Protein Signaling Mediated by Tubby
(p = 1.24E-02), Serotonin Receptor Signaling (p = 1.72E02) and UVB-Induced MAPK Signaling (p = 2.12E-02)
were identified as canonical pathways of interest (Table 2c).
IPA also identified DRD4 (Entrez Gene: 1815), a dopamine
receptor gene, to be the top upstream regulator of the
twenty-seven common genes. Similarly, IPA identified developmental disorders (p = 4.03E-04-1.21E-03) as a top
disease associated with this gene set while, Cell Signaling
(p = 4.03E-04-3.73E-02), Nucleic Acid Metabolism (p =
4.03E-04-3.73E-02) and gene expression (p = 3.62E-039.63E-03) have been revealed as significant molecular and
cellular functions. Also, Nervous System Development and
Function (p = 1.61E-03-1.61E-03) has been revealed as one
of the top physiological systems related to this gene set.
Further, Infectious Disease, Hereditary Disorders, Embryonic Development and Cell Death and Survival were
notable associated network functions related to the differentially methylated gene set in both schizophrenic twins.
When the 27 genes were analyzed using Enrichr [25], expression in whole brain was identified as the top human
gene atlas finding. Enrichr also identified OMIM disease
classifications related to neurodevelopment to be enriched
in our gene list; these include Asperger’s syndrome (p =
0.039) and mental retardation (p = 0.065).
Unrelated MZ twins discordant for schizophrenia have
differentially methylated networks; some pair specific and
others shared

IPA analysis on the DMRs identified in Family 1 shows
that they are implicated in Developmental Disorders

(p = 3.93E-03-3.21E-02), Hereditary Disorders (p = 3.93E03-4.58E-02), Skeletal and Muscular Disorders, (p =
3.93E-03-3.21E-02) and Neurological Disease (p = 4.77E03-3.54E-02) as these were the top diseases and disorders
associated with the DMR gene set (Table 2). Similarly, in
Family 2, they are implicated in Skeletal and Muscular
Disorders (p = 9.34E-04-4.07E-02) as a top disease and
disorder followed by Cancer (p = 2.09E-04-4.07E-02),
Gastrointestinal Disease (p = 8.86E-04-4.07E-02) and Organismal Injury and Abnormalities (p = 9.34E-04-3.94E02). This analysis also identified a number of interesting
canonical pathways including Human Embryonic Stem
Cell Pluripotency (p = 6.45E-05), Tec Kinase Signaling
(p = 1.51E-04) and IL-4 Signaling (p = 6.49E-03) in
Family 1. In contrast, the canonical pathways of interest
in Family 2 included Hepatic Cholestasis (p = 1.05E-04),
Granzyme A Signaling (p = 1.51E-03) and STAT3 Pathway (p = 3.31E-03). Other twin specific networks and
functions identified are listed in Tables 2a and b.
This analysis also identified two functional networks
that were affected in both unrelated twin pairs (Figure 5).
They included a cell death and survival network (ratio of
differentially methylated genes to total number of genes
in the network was 12/35 and 9/35, in Family 1 and
Family 2, respectively) (Figure 5a) and a cellular movement and immune cell trafficking network (14/35 and
11/35 genes in Family 1 and 2, respectively) (Figure 5b).
In Family 1, the Cell Death and Survival network identified IL1B (Entrez Gene: 3553) as the primary hub gene
of the network, while in Family 2, TP53 (Entrez Gene:
7157) was identified as the primary hub gene in this network. Similarly, the cellular movement and immune cell
trafficking networks involves TNF (Entrez Gene: 7124)
and IFNG (Entrez Gene: 3458) as hub genes in Family 1
and IGF1R (Entrez Gene: 3480) and EGFR (Entrez Gene:
1956) as hub genes in Family 2. The results may argue

Transcript

Chr Region start

Region end

Distance to TSS

Methylation
status

MAT score MAT score Found in Family 1 Found in Family 2
Family 1
Family 2
parental
parental

HIST2H2AA3

1

148085850

148085870

−3382

Increase

8.45215

12.7557

YES (Both)

YES (Mom)

HIST2H2AA4

1

148085850

148085870

−3382

Increase

8.45215

12.7557

YES (Both)

YES (Mom)

HIST2H3A

1

148085850

148085870

−4935

Increase

8.45215

12.7557

YES (Both)

YES (Mom)

HIST2H3C

1

148085850

148085870

−4935

Increase

8.45215

12.7557

YES (Both)

YES (Mom)

HIST1H1C

6

26164302

26164322

357

Increase

6.0215

7.54892

NO

NO

PTPRN2

7

F1:157141154 F2:157352628 F1:157141174 F2:157352648 F1:932070 F2:720596 Increase

2.41616

TTYH3

7

F1:2653547 F2:2664585

ZFP41

8

SNORD115-10 15

7.11519

NO

NO

F1:Increase F2:Decrease 2.47725

−2.82779

NO

NO

F1:144403919 F2:144409425 F1:144403939 F2:144409445 F1:3446 F2: 8952

Increase

2.05379

15.1625

NO

NO

22983806

Increase

7.8983

7.49051

YES (Both)

YES (Both)

F1:2653567 F2:2664605

22983826

F1:15418 F2:26456

30

SNORD115-11 15

22983806

22983826

−1828

Increase

7.8983

7.49051

YES (Both)

YES (Both)

SNORD115-12 15

22983806

22983826

1935

Increase

7.8983

7.49051

YES (Both)

YES (Both)

SNORD115-29 15

22983806

22983826

−1828

Increase

7.8983

7.49051

YES (Both)

YES (Both)

SNORD115-33 15

23030052

23030072

2974

Increase

7.8983

7.49051

YES (Both)

YES (Both)

SNORD115-34 15

23030052

23030072

1425

Increase

7.8983

7.49051

YES (Both)

YES (Both)

SNORD115-35 15

23030052

23030072

−415

Increase

7.8983

7.49051

YES (Both)

YES (Both)

SNORD115-36 15

22983806

22983826

−1828

Increase

7.8983

7.49051

YES (Both)

YES (Both)

SNORD115-37 15

23030052

23030072

−4154

Increase

7.8983

7.49051

YES (Both)

YES (Both)

SNORD115-43 15

22983806

22983826

−1828

Increase

7.8983

7.49051

YES (Both)

YES (Both)

SNORD115-5

15

22983806

22983826

1932

Increase

7.8983

7.49051

YES (Both)

YES (Both)

SNORD115-9

15

22983806

22983826

1935

Increase

7.8983

7.49051

YES (Both)

YES (Both)

SNORD116-10 15

22868070

22868090

−2263

Increase

7.8983

7.49051

YES (Both)

YES (Both)

SNORD116-11 15

22868070

22868090

−4078

Increase

7.8983

7.49051

YES (Both)

YES (Both)

SNORD116-3

15

22868070

22868090

−1256

Increase

7.8983

7.49051

YES (Both)

YES (Both)

SNORD116-8

15

22868070

22868090

1399

Increase

7.8983

7.49051

YES (Both)

YES (Both)

SNORD116-9

15

22868070

22868090

−1256

Increase

7.8983

7.49051

YES (Both)

YES (Both)

GNAS

20

56879799

56879819

18368

F1:Decrease F2:Increase −10.7502

17.2187

YES (Both)

YES (Both)

XIST

X

72974756

72974776

14538

F1:Decrease F2:Increase −7.36623

12.1903

YES (Both)

NO
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Table 1 Differentially methylated regions identified in two affected MZD twins belonging to two unrelated families

Chr = Chromosome, Region Start and Region End = Beginning and end of region, TSS = Distance to Transcript Start Site; F1 = Family 1; F2 = Family 2.
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Figure 4 Manhattan plot representing methylation in the 15q11.2-15q12 region in the twin pairs of Family 1. This region spans from SNRPN to
UBE3A and encompasses members of the SNORD115 and SNORD116 gene families (top). A red dot indicates a decrease in methylation in the
affected twin. A blue dot indicates an increase in methylation in the affected twin (Family 1). This region contains a complex regulatory ncRNA
involved in imprinting control and neurodevelopment.

that networks rather than genes may ultimately underlie
the etiology of schizophrenia and related disorders.

Discussion
The results included in this report support that monozygotic twins differ in DNA methylation. This difference is
genome-wide and includes a relatively large number of
presumed de novo events. The results suggest that de
novo methylation changes are common during development and aging in the two pairs studied. The results
therefore are specific to the two patients and will not
necessarily cover the whole spectrum of the disease.
Taken together, the results call for further assessment of
epigenetic profiles in an increased number of rare discordant twin pairs, as the analysis included in this report

is based on two female pairs only. The DMRs may represent random events over the lifetime or arise from
shared environmental conditions [20,21,26]. Further, although the two MZD pairs for schizophrenia are unrelated, they share differences in DNA methylation in 27
genes and genomic locations. Interestingly, many of
these shared differences belong to the histone coding
gene family, which has already been implicated in the
causation of schizophrenia [12,21,27]. Also, the differentially methylated genes affect two networks that are
compatible with the development of this neurodevelopmental disease. Finally, the genes identified have the potential to explain the discordance of the two twin pairs
for schizophrenia. Of special interest to this discussion
are HIST genes primarily located on chromosome 1 and

Castellani et al. BMC Medical Genomics (2015) 8:17
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Table 2 Ingenuity pathway analysis (IPA) results a) Family 1
b) Family 2 c) Subset of 27 genes found in both affected
twins

Table 2 Ingenuity pathway analysis (IPA) results a) Family 1
b) Family 2 c) Subset of 27 genes found in both affected
twins (Continued)

a. Family 1

Molecular Transport

1.88E-04 - 4.07E-02

9

Small Molecule Biochemistry

1.88E-04 - 4.07E-02

19

Cellular Growth and Proliferation

3.06E-04 - 4.07E-02

21

5.59E-04 - 3.63E-02

10

Biological function

P-value

Genes

Diseases and disorders
Developmental Disorder

3.93E-03 - 3.21E-02

10

Cell Morphology

Hereditary Disorder

3.93E-03 - 4.58E-02

19

Canonical pathways

Skeletal and Muscular Disorders

3.93E-03 - 3.21E-02

5

Hepatic Cholestasis

1.05E-04

9/141(0.064)

Neurological Disease

4.77E-03 - 3.54E-02

13

Granzyme A Signaling

1.51E-03

3/17 (0.176)

Ovarian Cancer Signaling

2.24E-03

7/138 (0.051)

Carbohydrate Metabolism

7.88E-04 - 2.06E-02

3

STAT3 Pathway

3.31E-03

5/74 (0.068)

Lipid Metabolism

7.88E-04 - 2.06E-02

3

Colorectal Cancer Metastasis Signaling

4.9E-03

9/244 (0.037)

Small Molecule Biochemistry

7.88E-04 - 4.58E-02

7

Physiological system development and function
Cardiovascular System Development
and Function

1.88E-04 - 4.07E-02

10

Digestive System Development and
Function

1.88E-04 - 1.88E-04

2

Embryonic Development

1.88E-04 - 4.07E-02

14

1.88E-04 - 4.07E-02

6

Molecular and cellular functions

Gene Expression

2.63E-03 - 4.58E-02

18

Cell Death and Survival

5.20E-03 - 3.16E-02

13

Canonical pathways
Human Embryonic Stem Cell
Pluripotency

6.45E-05

6/149 (0.04)

Tec Kinase Signaling

1.51E-04

6/175 (0.034)

Organ Development

Sphingosine-1-phosphate Signaling

2.42E-03

4/115 (0.035)

Associated network functions

Renal Cell Carcinoma Signaling

5.55E-03

3/71 (0.042)

IL-4 Signaling

6.49E-03

3/75 (0.04)

Cell Death and Survival, Cellular Development, Connective Score = 39
Tissue Development and Function

Physiological system development and function

Cellular Movement, Immune Cell Trafficking,
Hematological System Development and Function

Score = 12

Cardiovascular System Development
and Function

5.20E-03 - 3.58E-02

1

Cancer, Organismal Injury and Abnormalities, Reproductive Score = 11
System Disease

Hair and Skin Development and
Function

5.20E-03 - 4.58E-02

2

Cell Death and Survival, Cellular Movement, Renal
Necrosis/Cell Death

Score = 11

Hematological System Development
and Function

5.20E-03 - 4.13E-02

7

Cell Morphology, Cellular Function and Maintenance, Cell
Cycle

Score = 9

Immune Cell Trafficking

5.20E-03 - 4.13E-02

3

c. Shared DMRs between both families

Associated network functions
Cell Death and Survival, Cellular Movement, Cellular
Function and Maintenance

Score = 19

Cellular Movement, Immune Cell Trafficking,
Hematological System Development and Function

Score = 17

Hereditary Disorder, Skeletal and Muscular Disorders,
Developmental Disorder

Score = 9

Connective Tissue Disorders, Dermatological Diseases and
Conditions, Hematological System Development and
Function

Score = 2

Organ Morphology, Reproductive System Development
and Function, Cellular Function and Maintenance

Score = 2

Cancer

4.03E-04 - 4.50E-02

5

Connective Tissue Disorders

4.03E-04 - 8.05E-04

1

Developmental Disorder

4.03E-04 - 1.21E-03

1

Endocrine System Disorders

4.03E-04 - 4.50E-02

2

4.03E-04 - 3.73E-02

1

Molecular and cellular functions
Cell Signaling

b. Family 2

Nucleic Acid Metabolism

4.03E-04 - 3.73E-02

1

Small Molecule Biochemistry

4.03E-04 - 3.73E-02

1

Gene Expression

3.62E-03 - 9.63E-03

1

Cellular Movement

6.43E-03 - 6.43E-03

1

Canonical pathways

Cancer

2.09E-04 - 4.07E-02

204

Protein Kinase A Signaling

3.09E-04

3/368 (0.008)

Gastrointestinal Disease

8.86E-04 - 4.07E-02

29

Granzyme A Signaling

6.83E-03

1/17 (0.059)

Organismal Injury and Abnormalities

9.34E-04 - 3.94E-02

46

1.24E-02

1/31 (0.032)

Skeletal and Muscular Disorders

9.34E-04 - 4.07E-02

36

G Protein Signaling Mediated by
Tubby
Serotonin Receptor Signaling

1.72E-02

1/43 (0.023)

UVB-Induced MAPK Signaling

2.12E-02

1/53 (0.019)

Molecular and cellular functions
Lipid Metabolism

1.88E-04 - 4.07E-02

7
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Table 2 Ingenuity pathway analysis (IPA) results a) Family 1
b) Family 2 c) Subset of 27 genes found in both affected
twins (Continued)
Physiological system development and function
Nervous System Development and
Function

1.61E-03 - 1.61E-03

1

Hematological System Development
and Function

6.43E-03 - 2.47E-02

1

Immune Cell Trafficking

6.43E-03 - 6.43E-03

1

Behavior

2.04E-02 - 2.04E-02

1

Associated network functions
Infectious Disease, Cancer, Gastrointestinal Disease

Score = 3

Tissue Morphology, Organismal Survival, Gene Expression

Score = 3

Hereditary Disorder, Gene Expression, Embryonic
Development

Score = 3

DNA Replication, Recombination, and Repair, Gene
Expression, Cancer

Score = 3

Cell Death and Survival, Cellular Function and
Maintenance, Connective Tissue Development and
Function

Score = 3

SNORD115 and SNORD116 genes located on chromosome 15. In addition, the two patients share identified
networks affecting cell death and immune cell trafficking, which are elaborated on below.
It is noteworthy that our study identified 5 HIST genes
as genes of interest in the discordance for schizophrenia.
A Histone gene cluster on Chromosome 6 has been previously implicated in a meta-analysis of schizophrenia
associated loci in individuals of European ancestry [28].
The implicated region itself, 6p22.1, was also found to
be associated with schizophrenia [28]. In addition, histone methylation has been found in olfactory cells implicating oxidative stress in schizophrenia [29]. Lastly,
postmortem brain tissue from schizophrenia patients
has been found to have higher levels of histone deacetylase, HDAC1, and the level of HDAC1 has been shown
to be inversely correlated with GAD67 (Entrez Gene:
2571) protein expression, which tends to be decreased in
schizophrenia patients [30,31] and argues that histones
may play a role in this complex disease.
The SNPRN-UBE3A locus, which encompasses the
SNORD115 and SNORD116 gene families, is a complex
non-coding RNA region that spans 15q11-q13 [32].
Noncoding RNAs, including miRNAs, are known to
fine-tune gene expression through transcriptional and
post-transcriptional regulations including RNA stability
and protein translation [33]. In addition to serving as an
antisense RNA for UBE3A, the polycistronic transcript is
also a host that undergoes extensive processing, including the production of a number of small nucleolar RNA
species (snoRNAs). The HBII-52 snoRNAs (also known as
the SNORD115 family) regulate the alternative splicing of

the 5HTR2C serotonin receptor and result in an increased
serotonin response in neurons [34]. SNORD115 is further
processed into processed snoRNAs (psnoRNAs) that go
on to regulate alternative splicing in a number of other
transcripts, including epigenomic modifiers [35]. However, a conflicting report emerged in 2012 that showed
evidence against psnoRNAs, indicating that SNORD115
and SNORD116 may generate genuine snoRNAs [36].
A novel ncRNA species, LncRNAs with snoRNA ends,
also originates from this loci. They are functionally distinct from snoRNAs and lncRNAs and are associated
with the FOX family of splicing regulators that alter the
alternative splicing of a number of other genes. In
addition to psnoRNAs, snoRNAs, and lnc-snoRNAs,
the snoRNAs are even further processed into snoRNAderived RNAs (sdRNAs). These sdRNAs are proposed
to come in two variations: some resembling miRNAs
that associate with argonaute proteins to regulate
translation and another longer type that form complexes to influence gene expression [37]. Further investigation into the locus has shown that it produces even
more ncRNA products, with the introns forming the
snoRNA derivatives and the exons forming two distinct
but overlapping neuronal lncRNA clouds from the
SNORD 115 and SNORD116 regions that are involved
in modulating circadian rhythm and energy expenditure [38,39]. The lncRNAs are functionally distinct
from the earlier identified ncRNA species and are also
primarily expressed in developing neurons.
Interestingly, the lncRNA from the SNPRN-UBE3A region has been suggested to regulate another imprinted
locus, the DLK1-DIO3 region, which is the only other
known imprinted cluster of ncRNA that produces lncRNA,
miRNA, and snoRNA. It is also involved in neurodevelopment and suggests that imprinted ncRNAs are capable of
‘genomic cross-talk’ [40,41]. Interestingly, while imprinting
disorders are known to originate from these loci, a
highly resolved and restricted deletion in the SNORD116
region was identified as the minimal mutation to cause
Prader-Willi Syndrome [42]. Also, DRD4, a top upstream
regulator identified in the shared DMR gene set, has been
previously implicated in schizophrenia, and is thought to
be the target of many antipsychotics [43].
The identified networks across unrelated twins share
common functions supporting the hypothesis that a different set of patient specific gene insults may lead to disease symptoms. There has been a long held linkage
between schizophrenia and immune cell function. This
theory gained further support as novel functions of immune molecules in the brain and cross-talk between the
immune system and the central nervous system [44]. In
addition, a number of studies have shown up-regulation
of immune-inflammatory genes in the CNS [44-46] as
well as immune system gene modulation of synaptic
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Figure 5 Common networks identified in both families. a. Two cell death and survival networks independently identified in each affected twin in
our study. Ingenuity Pathway Analysis (IPA) was used to identify the networks in both affected twins in our study. Shading represents genes in
our study that are differentially methylated in the network. b. Two cellular movement and immune cell trafficking networks independently identified in
each affected twin in our study. Ingenuity Pathway Analysis (IPA) was used to identify the networks in both affected twins in our study. Shading
represents genes in our study that are differentially methylated in the network.

function [47]. In the cellular movement and immune cell
trafficking networks identified in Family 1, two genes (TNF
and IFNG) immerged as hub genes. The tumor necrosis
factor (TNFα) had been associated with schizophrenia and
also it was reported that immune dysregulation could have
a genetic component in schizophrenia patients [48]. Also,
a single nucleotide polymorphism in the interferon gamma
gene (IFNG) had been associated with paranoid schizophrenia in males [49], however, the role of the gene in the
pathophysiology of the disease remains to be elucidated.
Similarly, the other hub gene of cellular movement and
immune cell trafficking network, EGFR, identified in Family 2 have also been associated with schizophrenia [50].

The primary hub gene in the Cell Death and Survival
network, IL1B, which is differentially methylated in Family
1, has an important role in the development of the central
nervous system. Also, it is reported to be associated with
schizophrenia [51]. Similarly, the human p53 tumor suppressor gene (TP53), which is identified as a primary hub
gene in the cell death and survival network of Family 2 in
this study, plays a role in neurodevelopment and was previously associated with schizophrenia [52].
Finally, the question of the effect of the observed DNA
methylation on disease must be interpreted with caution.
We may add that most schizophrenia patients are exposed to antipsychotic drugs in North America. Our
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patients were under treatment with medications, though
not consistently. We note that such drugs and cellular
heterogeneity of the studied samples [53] may also affect
DNA methylation [54] as confounding factors. Further,
although practical, we recognize the use of blood to
make inferences regarding a brain-based disorder is not
without caution and recommend that this discovery
study be complemented by population studies of larger
sample size on this disease as well as confirmation of the
findings using alternative technologies. However, in its
current state, it is not possible to eliminate these and
other confounding factors that may affect our results at
this time. The specific observations on genes and pathways relevant to the disease however, lend support to
the complexity of this neurodevelopmental disease and
its aetiology.
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Conclusions
We report genome-wide methylation differences between monozygotic twins discordant for schizophrenia.
A number of genes and networks identified are twin
pair-specific, while others are shared between unrelated
patients. Most patient specific genes and gene networks
affected have been previously implicated in schizophrenia.
Specifically, the results identify three sets of gene clusters, HIST (Chromosome 1), SNORD115 and SNORD116
(Chromosome 15), which are differentially methylated in
the twins with schizophrenia as compared to their unaffected counterpart. We also report common networks
identified independently in the two patients that relate to
cell death/survival and immune cell trafficking networks
disrupted in schizophrenia. The results on monozygotic
discordant twins argue for a network based rather than
gene focused approach in the understanding of schizophrenia and related disorders.
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